UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy

Ivan Presta1, Fabiana Novellino2, Annalidia Donato3

  • 1Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.

Insights

The mitotic ubiquitin-conjugating enzyme UbcH10 is overexpressed in many cancers, driving proliferation and metastasis. Gene silencing can reverse these effects, suggesting UbcH10 as a diagnostic and therapeutic target in human malignancies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Malignant transformation involves dysregulated cell proliferation pathways.
  • The mitotic ubiquitin-conjugating enzyme UbcH10 (also known as UBE2C) is frequently overexpressed in various human cancers.
  • UbcH10 plays a critical role in cell cycle regulation.

Purpose of the Study:

  • To review the literature on UbcH10 in human cancer.
  • To highlight the association between UbcH10 overexpression and cancer progression.
  • To discuss the diagnostic and therapeutic potential of UbcH10.

Main Methods:

  • Literature review of studies on UbcH10 in human cancer.
  • Analysis of immunohistochemistry and RT-PCR data for UbcH10 expression.
  • Review of gene silencing studies investigating UbcH10's role.

Main Results:

  • UbcH10 overexpression is linked to an exacerbated cancer phenotype.
  • Immunohistochemistry and RT-PCR can differentiate malignant neoplasms from normal or benign tissues based on UbcH10 levels.
  • Gene silencing of UbcH10 reverses cancer-associated phenotypes like increased proliferation, metastasis, and drug resistance.

Conclusions:

  • UbcH10 evaluation in cancer patients shows promise as a diagnostic and therapeutic tool.
  • Clinical application of knowledge regarding UbcH10's role in carcinogenesis is advocated.
  • Targeting UbcH10 could offer new strategies for cancer treatment.